Postmenopausal Hormone Therapy and Breast Cancer Risk: Current Status and Unanswered Questions

Endocrinology and Metabolism Clinics of North America

Volumn 40, Issue 3, 2011, Pages 509-518

  Chen, Wendy Y ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Breast cancer; Estrogen; Hormone therapy; Menopause

Indexed keywords

AROMATASE INHIBITOR; CONJUGATED ESTROGEN; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; ETHINYLESTRADIOL; HORMONE; MEDROXYPROGESTERONE ACETATE; NORETHISTERONE; NORGESTREL; PLACEBO; PROGESTERONE; PROGESTERONE RECEPTOR; SEROTONIN UPTAKE INHIBITOR; TAMOXIFEN; TESTOSTERONE; TIBOLONE;

AGE; BODY MASS; BREAST CANCER; BREAST CARCINOGENESIS; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CANCER SIZE; CANCER SURVIVOR; CLINICAL TRIAL (TOPIC); DISEASE ASSOCIATION; DOSE CALCULATION; DRUG CHOICE; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; FAMILY HISTORY; HORMONAL THERAPY; HUMAN; MEDICAL DECISION MAKING; MEDICAL SOCIETY; MENOPAUSAL SYNDROME; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; TREATMENT DURATION;

BREAST NEOPLASMS; CARCINOMA; CONSENSUS; DISSENT AND DISPUTES; ENDOCRINOLOGY; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; PRACTICE GUIDELINES AS TOPIC; RISK FACTORS;

EID: 80052238661     PISSN: 08898529     EISSN: 15584410     Source Type: Journal    
DOI: 10.1016/j.ecl.2011.05.006     Document Type: Review

References (48)

1. Faber A., Bouvy M.L., Loskamp L., et al. Dramatic change in prescribing of hormone replacement therapy in The Netherlands after publication of the Million Women Study: a follow-up study. Br J Clin Pharmacol 2005, 60:641-647.
2. Hersh A.L., Stefanick M.L., Stafford R.S. National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA 2004, 291:47-53.
3. Watson J., Wise L., Green J. Prescribing of hormone therapy for menopause, tibolone, and bisphosphonates in women in the UK between 1991 and 2005. Eur J Clin Pharmacol 2007, 63:843-849.
4. Rossouw J.E., Anderson G.L., Prentice R.L., et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002, 288:321-333.
5. Anderson G.L., Limacher M., Assaf A.R., et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004, 291:1701-1712.
6. Chlebowski R.T., Hendrix S.L., Langer R.D., et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA 2003, 289:3243-3253.
7. McTiernan A., Martin C.F., Peck J.D., et al. Estrogen-plus-progestin use and mammographic density in postmenopausal women: Women's Health Initiative randomized trial. J Natl Cancer Inst 2005, 97:1366-1376.
8. Chlebowski R.T., Anderson G., Pettinger M., et al. Estrogen plus progestin and breast cancer detection by means of mammography and breast biopsy. Arch Intern Med 2008, 168:370-377. [quiz: 345].
9. Banks E., Reeves G., Beral V., et al. Hormone replacement therapy and false positive recall in the Million Women Study: patterns of use, hormonal constituents and consistency of effect. Breast Cancer Res 2006, 8:R8.
10. Chlebowski R.T., Kuller L.H., Prentice R.L., et al. Breast cancer after use of estrogen plus progestin in postmenopausal women. N Engl J Med 2009, 360:573-587.
11. Stefanick M.L., Anderson G.L., Margolis K.L., et al. Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA 2006, 295:1647-1657.
12. McTiernan A., Chlebowski R.T., Martin C., et al. Conjugated equine estrogen influence on mammographic density in postmenopausal women in a substudy of the Women's Health Initiative randomized trial. J Clin Oncol 2009, 27:6135-6143.
13. Chlebowski R.T., Anderson G., Manson J.E., et al. Estrogen alone in postmenopausal women and breast cancer detection by means of mammography and breast biopsy. J Clin Oncol 2010, 28:2690-2697.
14. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet 1997, 350:1047-1059. [see comments] [Erratum appears in Lancet 1997;350(9089):1484].
15. Beral V. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003, 362:419-427.
16. Hormone therapy for the prevention of chronic conditions in postmenopausal women: recommendations from the U.S. Preventive Services Task Force. Ann Intern Med 2005, 142:855-860. U.S. Preventive Services Task Force.
17. ACOG Committee Opinion No. 420, November 2008: hormone therapy and heart disease. Obstet Gynecol 2008, 112:1189-1192. American College of Obstetricians, Gynecologists Committee on Gynecologic Practice.
18. Gompel A., Rozenberg S., Barlow D.H. The EMAS 2008 update on clinical recommendations on postmenopausal hormone replacement therapy. Maturitas 2008, 61:227-232. EMAS board members.
19. Estrogen and progestogen use in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause 2010, 17:242-255. North American Menopause Society.
20. Rossouw J., Prentice R., Manson J., et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007, 297:1465-1477.
21. Fournier A., Mesrine S., Boutron-Ruault M.C., et al. Estrogen-progestagen menopausal hormone therapy and breast cancer: does delay from menopause onset to treatment initiation influence risks?. J Clin Oncol 2009, 27:5138-5143.
22. Miller V.M., Black D.M., Brinton E.A., et al. Using basic science to design a clinical trial: baseline characteristics of women enrolled in the Kronos Early Estrogen Prevention Study (KEEPS). J Cardiovasc Transl Res 2009, 2:228-239.
23. Chlebowski R.T., Anderson G.L., Gass M., et al. Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA 2010, 304:1684-1692.
24. Chen W.Y., Colditz G.A. Risk factors and hormone-receptor status: epidemiology, risk-prediction models and treatment implications for breast cancer. Nat Clin Pract Oncol 2007, 4:415-423.
25. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005, 365:1687-1717. Early Breast Cancer Trialists' Collaborative Group (EBCTCG).
26. Chen W.Y., Manson J.E., Hankinson S.E., et al. Unopposed estrogen therapy and the risk of invasive breast cancer. Arch Intern Med 2006, 166:1027-1032.
27. Rohan T.E., Negassa A., Chlebowski R.T., et al. Conjugated equine estrogen and risk of benign proliferative breast disease: a randomized controlled trial. J Natl Cancer Inst 2008, 100:563-571.
28. Fournier A., Berrino F., Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat 2008, 107:103-111.
29. Stahlberg C., Pedersen A.T., Lynge E., et al. Increased risk of breast cancer following different regimens of hormone replacement therapy frequently used in Europe. Int J Cancer 2004, 109:721-727.
30. Lyytinen H., Pukkala E., Ylikorkala O. Breast cancer risk in postmenopausal women using estradiol-progestogen therapy. Obstet Gynecol 2009, 113:65-73.
31. Tamimi R.M., Hankinson S.E., Chen W.Y., et al. Combined estrogen and testosterone use and risk of breast cancer in postmenopausal women. Arch Intern Med 2006, 166:1483-1489.
32. Ness R.B., Albano J.D., McTiernan A., et al. Influence of estrogen plus testosterone supplementation on breast cancer. Arch Intern Med 2009, 169:41-46.
33. Ewertz M. Influence of non-contraceptive exogenous and endogenous sex hormones on breast cancer risk in Denmark. Int J Cancer 1988, 42:832-838.
34. Kaaks R., Berrino F., Key T., et al. Serum sex steroids in premenopausal women and breast cancer risk within the European Prospective Investigation into Cancer and Nutrition (EPIC). J Natl Cancer Inst 2005, 97:755-765.
35. Key T., Appleby P., Barnes I., et al. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 2002, 94:606-616.
36. Fournier A., Berrino F., Riboli E., et al. Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. Int J Cancer 2005, 114:448-454.
37. Olsson H., Bladstrom A., Ingvar C., et al. A population-based cohort study of HRT use and breast cancer in southern Sweden. Br J Cancer 2001, 85:674-677.
38. Sellers T.A., Mind P.J., Cerhan J.R., et al. The role of hormone replacement therapy in the risk for breast cancer and total mortality in women with a family history of breast cancer. Ann Intern Med 1997, 127:973-980.
39. Gramling R., Eaton C.B., Rothman K.J., et al. Hormone replacement therapy, family history, and breast cancer risk among postmenopausal women. Epidemiology 2009, 20:752-756.
40. Magnusson C., Baron J.A., Correia N., et al. Breast-cancer risk following long-term oestrogen- and oestrogen-progestin-replacement therapy. Int J Cancer 1999, 81:339-344.
41. Schairer C., Lubin J., Troisi R., et al. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA 2000, 283:485-491.
42. Brinton L.A., Richesson D., Leitzmann M.F., et al. Menopausal hormone therapy and breast cancer risk in the NIH-AARP Diet and Health Study Cohort. Cancer Epidemiol Biomarkers Prev 2008, 17:3150-3160.
43. Reeves G.K., Beral V., Green J., et al. Million Women Study Collaborators. Hormonal therapy for menopause and breast-cancer risk by histological type: a cohort study and meta-analysis. Lancet Oncol 2006, 7:910-918.
44. Kerlikowske K., Cook A.J., Buist D.S., et al. Breast cancer risk by breast density, menopause, and postmenopausal hormone therapy use. J Clin Oncol 2010, 28:3830-3837.
45. Vassilopoulou-Sellin R., Cohen D.S., Hortobagyi G.N., et al. Estrogen replacement therapy for menopausal women with a history of breast carcinoma: results of a 5-year, prospective study. Cancer 2002, 95:1817-1826.
46. von Schoultz E., Rutqvist L.E. Menopausal hormone therapy after breast cancer: the Stockholm randomized trial. J Natl Cancer Inst 2005, 97:533-535.
47. Holmberg L., Iversen O.E., Rudenstam C.M., et al. Increased risk of recurrence after hormone replacement therapy in breast cancer survivors. J Natl Cancer Inst 2008, 100(7):475-482.
48. Kenemans P., Bundred N.J., Foidart J.M., et al. Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial. Lancet Oncol 2009, 10:135-146.